拉考沙胺在儿童癫痫中的治疗药物监测研究进展

李玥, 郭宏丽, 赵越桃, 胡雅慧, 卢孝鹏, 陈静, 陈峰

中国药学杂志 ›› 2023, Vol. 58 ›› Issue (19) : 1731-1735.

PDF(942 KB)
中国药学杂志
PDF(942 KB)
中国药学杂志 ›› 2023, Vol. 58 ›› Issue (19) : 1731-1735. DOI: 10.11669/cpj.2023.19.002
综述

拉考沙胺在儿童癫痫中的治疗药物监测研究进展

  • 李玥1, 郭宏丽1, 赵越桃1,2, 胡雅慧1, 卢孝鹏3, 陈静3, 陈峰1*
作者信息 +

An Updated Review on Therapeutic Drug Monitoring of Lacosamide for Children with Epilepsy

  • LI Yue1, GUO Hongli1, ZHAO Yuetao1,2, HU Yahui1, LU Xiaopeng3, CHEN Jing3, CHEN Feng1*
Author information +
文章历史 +

摘要

拉考沙胺(lacosamide,LCM)作为第三代抗癫痫发作药物,于2021年在我国被批准用于4岁及以上部分性发作患者的单药治疗。本文通过回顾分析LCM应用于儿童癫痫的国内外相关研究,旨在总结和讨论LCM在这一特殊群体中的目标血药浓度范围及影响因素。相关研究表明,生理病理、联合用药、药物代谢酶编码基因的遗传多态性等多种因素会对LCM药动学过程产生影响。应强调的是,虽然LCM在治疗我国儿童癫痫时的最佳血药浓度报道较少,但有研究表明,2~10 μg·mL-1可考虑作为LCM治疗儿童期癫痫的目标血药浓度范围。当然,关于LCM在儿童人群的治疗药物监测和目标治疗浓度范围有待高质量的临床试验进一步研究。

Abstract

As one of the third-generation of antiseizure medications, lacosamide (LCM) was approved in China to treat focal-onset seizures in people of 4 years of age and older in 2021, which has attracted widespread attention. This article reviews the relevant studies on the application of LCM for childhood epilepsy treatment, aiming to summarize the research on therapeutic drug monitoring and discuss the reference range of plasma LCM levels and its determinants. Studies showed that the pharmacokinetics of LCM was affected by many factors, like physiopathology, co-medications, and genetic polymorphisms of drug-metabolizing enzymes. However, there were rare reports on blood LCM concentration in treating childhood epilepsy in China, but the limited research in recent years supported that (2-10) μg·mL-1 could be seen as the reference plasma concentration range. Assuredly, the therapeutic drug monitoring and target range of plasma LCM levels in children with epilepsy need to be further studied in high-quality clinical trials.

关键词

拉考沙胺 / 治疗药物监测 / 癫痫 / 儿童

Key words

lacosamide / therapeutic drug monitoring / epilepsy / children

引用本文

EndNote

Ris (Procite)

Bibtex

导出引用
李玥, 郭宏丽, 赵越桃, 胡雅慧, 卢孝鹏, 陈静, 陈峰. 拉考沙胺在儿童癫痫中的治疗药物监测研究进展[J]. 中国药学杂志, 2023, 58(19): 1731-1735 https://doi.org/10.11669/cpj.2023.19.002
LI Yue, GUO Hongli, ZHAO Yuetao, HU Yahui, LU Xiaopeng, CHEN Jing, CHEN Feng. An Updated Review on Therapeutic Drug Monitoring of Lacosamide for Children with Epilepsy[J]. Chinese Pharmaceutical Journal, 2023, 58(19): 1731-1735 https://doi.org/10.11669/cpj.2023.19.002
中图分类号： R971.6   

参考文献

[1] YANG C S, YU D, LI J, et al. Prevalence of medication adherence and factors influencing adherence to antiepileptic drugs in children with epilepsy from western China: a cross-sectional survey . Epilepsy Behav, 2020, 104(Pt A): 106662.DOI: 10.1016/j.yebeh.2019.106662.
[2] DING D, ZHOU D, SANDER J W, et al. Epilepsy in China: major progress in the past two decades . Lancet Neurol, 2021, 20(4): 316-326.
[3] CARONA A, BICKER J, SILVA R, et al. Pharmacology of lacosamide: from its molecular mechanisms and pharmacokinetics to future therapeutic applications . Life Sci, 2021, 275: 119342.DOI: 10.1016/j.lfs.2021.119342.
[4] NEAL A, D′SOUZA W, HEPWORTH G, et al. Efficacy and tolerability of adjuvant lacosamide: the role of clinical characteristics and mechanisms of action of concomitant AEDs . Epilepsy Behav, 2018, 80: 25-32. DOI: 10.1016/j.yebeh.2017.11.027.
[5] HMAIMESS G, SABBAGH S, DIRANI M, et al. Efficacy and tolerability of treatment with lacosamide in children: post marketing experience from the Middle East . Seizure, 2020, 79: 75-79. DOI: 10.1016/j.seizure.2020.04.016.
[6] TOUNTOPOULOU M, WESCHKE B, KAINDL A M. Lacosamide lowers valproate and levetiracetam levels . Neuropediatrics, 2017, 48(3): 188-189.
[7] RUEGGER A D, FREEMAN J L, HARVEY A S. Lacosamide in children with drug-resistant epilepsy . J Paediatr Child Health, 2019, 55(2): 194-198.
[8] YILDIZ E P, OZKAN M U, BEKTAS G, et al. Lacosamide treatment of childhood refractory focal epilepsy: the first reported side effect in paediatric patients . Childs Nerv Syst, 2017, 33(11): 2023-2027.
[9] MAY T W, HELMER R, BIEN C G, et al. Influence of dose and antiepileptic ccomedication on lacosamide serum concentrations in patients with epilepsy of different ages . Ther Drug Monit, 2018, 40(5): 620-627.
[10] WINKLER J, SCHOEMAKER R, STOCKIS A. Modeling and simulation for the evaluation of dose adaptation rules of intravenous lacosamide in children . Epilepsy Res, 2019, 149: 13-16. DOI: 10.1016/j.eplepsyres.2018.10.011.
[11] PERRENOUD M, ANDRE P, ALVAREZ V, et al. Intravenous lacosamide in status epilepticus: correlation between loading dose, serum levels, and clinical response . Epilepsy Res, 2017, 135: 38-42. DOI: 10.1016/j.eplepsyres.2017.05.007.
[12] NGAMPOOPUN M, SUWANPAKDEE P, JAISUPA N, et al. Effectiveness and adverse effect of intravenous lacosamide in nonconvulsive status epilepticus and acute repetitive seizures in children . Neurol Res Int, 2018, 2018: 8432859. DOI: 10.1155/2018/8432859.
[13] MAY T W, BRANDT C, HELMER R, et al. Comparison of lacosamide concentrations in cerebrospinal fluid and serum in patients with epilepsy . Epilepsia, 2015, 56(7): 1134-1140.
[14] BRANDT C, BIEN C G, HELMER R, et al. Assessment of the correlations of lacosamide concentrations in saliva and serum in patients with epilepsy . Epilepsia, 2018, 59(4): e34-e39.
[15] DE BIASE S, VALENTE M, GIGLI G L, et al. Pharmacokinetic drug evaluation of lacosamide for the treatment of partial-onset seizures . Expert Opin Drug Metab Toxicol, 2017, 13(9): 997-1005.
[16] WINKLER J, SCHOEMAKER R, STOCKIS A. Population pharmacokinetics of adjunctive lacosamide in pediatric patients with epilepsy . J Clin Pharmacol, 2019, 59(4): 541-547.
[17] YAMAMOTO Y, TERADA K, ARAKI Y, et al. Therapeutic monitoring of lacosamide in Japanese patients with epilepsy: clinical response, tolerability, and optimal therapeutic range . Ther Drug Monit, 2020, 42(5): 754-759.
[18] SVENDSEN T, BRODTKORB E, BAFTIU A, et al. Therapeutic drug monitoring of lacosamide in Norway: focus on pharmacokinetic variability, efficacy and tolerability . Neurochem Res, 2017, 42(7): 2077-2083.
[19] CONTIN M, ALBANI F, RIVA R, et al. Lacosamide therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs . Ther Drug Monit, 2013, 35(6): 849-852.
[20] LARSEN BURNS M, NIKANOROVA M, BAFTIU A, et al. Pharmacokinetic variability and clinical use of lacosamide in children and adolescents in Denmark and Norway . Ther Drug Monit, 2019, 41(3): 340-347.
[21] REIMERS A, BERG J A, BURNS M L, et al. Reference ranges for antiepileptic drugs revisited: a practical approach to establish national guidelines . Drug Des Devel Ther, 2018, 12: 271-280. DOI: 10.2147/DDDT.S154388.
[22] LI Y, GUO H L, ZHANG Y Y, et al. Plasma lacosamide monitoring in children with epilepsy: Focus on reference therapeutic range and influencing factors . Front Pediatr, 2022, 10: 949783. DOI: 10.3389/fped.2022.949783.
[23] ZHAO T, SUN Y, ZHANG H L, et al. Efficacy and serum concentration of lacosamide in children with epilepsy . Chin Pharm J (中国药学杂志), 2022, 57(5): 403-407.
[24] SCHULTZ L, MAHMOUD S H. Is therapeutic drug monitoring of lacosamide needed in patients with seizures and epilepsy? . Eur J Drug Metab Pharmacokinet, 2020, 45(3): 315-349.
[25] OTERO TORRES S, JUVANY ROIG R, FALIP CENTELLAS M, et al. Therapeutic drug monitoring of lacosamide: is 10 to 20 mg/L a suitable reference range for patients with epilepsy? . Clin Neuropharmacol, 2022, DOI: 10.1097/WNF.0000000000000537.
[26] LI H J, SUN Y, ZHAO T, et al. Influencing factors of serum concentration of lacosamide in epileptic children in Xinjiang . Chin J Hosp Pharm (中国医院药学杂志), 2021, 41(13): 1323-1326,1346.
[27] ZUTSHI D, YARRAGUNTLA K, MAHULIKAR A, et al. Racial variations in lacosamide serum concentrations in adult patients with epilepsy . J Neurol Sci, 2020, 412: 116742. DOI: 10.1016/j.jns.2020.116742.
[28] WIERUSZEWSKI P M, LOPEZ-RUIZ A, ALBRIGHT R C, et al. Lacosamide pharmacokinetics in a critically ill patient during continuous renal replacement therapy . J Pharm Pract, 2020, 33(3): 395-398.
[29] CAWELLO W, FUHR U, HERING U, et al. Impact of impaired renal function on the pharmacokinetics of the antiepileptic drug lacosamide . Clin Pharmacokinet, 2013, 52(10): 897-906.
[30] LIPAROTI G, BURCHIANI B, MENCARONI E, et al. Individualizing doses of antiepileptic drugs . Expert Opin Drug Metab Toxicol, 2022, 18(3): 219-233.
[31] DOTY P, RUDD G D, STOEHR T, et al. Lacosamide . Neurotherapeutics, 2007, 4(1): 145-148.
[32] PROBST-SCHENDZIELORZ K, VIVIANI R, STINGL J C. Effect of Cytochrome P450 polymorphism on the action and metabolism of selective serotonin reuptake inhibitors . Expert Opin Drug Metab Toxicol, 2015, 11(8): 1219-1232.
[33] LIMA J J, THOMAS C D, BARBARINO J, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2C19 and proton pump inhibitor dosing . Clin Pharmacol Ther, 2021, 109(6): 1417-1423.
[34] PETROVIC J, PESIC V, LAUSCHKE V M. Frequencies of clinically important CYP2C19 and CYP2D6 alleles are graded across Europe . Eur J Hum Genet, 2020, 28(1): 88-94.
[35] ZHOU S F, LIU J P, CHOWBAY B. Polymorphism of human cytochrome P450 enzymes and its clinical impact . Drug Metab Rev, 2009, 41(2): 89-295.
[36] AHN S J, OH J, KIM D Y, et al. Effects of CYP2C19 genetic polymorphisms on the pharmacokinetics of lacosamide in Korean patients with epilepsy . Epilepsia, 2022, 63(11): 2958-2969.
[37] LOPEZ-GARCIA M A, FERIA-ROMERO I A, SERRANO H, et al. Influence of genetic variants of CYP2D6, CYP2C9, CYP2C19 and CYP3A4 on antiepileptic drug metabolism in pediatric patients with refractory epilepsy . Pharmacol Rep, 2017, 69(3): 504-511.
[38] SILVADO C E, TERRA V C, TWARDOWSCHY C A. CYP2C9 polymorphisms in epilepsy: influence on phenytoin treatment . Pharmacogenom Pers Med, 2018, 11: 51-58. DOI: 10.2147/PGPM.S108113.
[39] YASAR U, ELIASSON E, DAHL M L, et al. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population . Biochem Biophys Res Commun, 1999, 254(3): 628-631.
[40] ELTALAL S, EL AYOUTY M, EL-SAID A, et al. CYP2C9 (*2&*3) and CYP2C19 (*2&*3) polymorphisms among children with nonlesional epilepsy: a single-center study . Acta Neurol Belg, 2021, 121(6): 1623-1631.
[41] CHAUDHARY N, KABRA M, GULATI S, et al. Frequencies of CYP2C9 polymorphisms in North Indian population and their association with drug levels in children on phenytoin monotherapy . BMC Pediatr, 2016, 16: 66. DOI: 10.1186/s12887-016-0603-0.
[42] ENRIQUE A V, DI IANNI M E, GOICOECHEA S, et al. New anticonvulsant candidates prevent P-glycoprotein (P-gp) overexpression in a pharmacoresistant seizure model in mice . Epilepsy Behav, 2021, 121(Pt B): 106451. DOI: 10.1016/j.yebeh.2019.106451.
[43] XUE T, LU Z N. Association between the polymorphisms in the ATP-binding cassette genes ABCB1 and ABCC2 and the risk of drug-resistant epilepsy in a Chinese Han population . Genet Mol Res, 2016, 15(4). DOI: 10.4238/gmr15048752.
[44] ZHAO T, LI H J, FENG J, et al. Impact of ABCB1 polymorphisms on lacosamide serum concentrations in Uygur pediatric patients with epilepsy in China . Ther Drug Monit, 2022, 44(3): 455-464.
[45] ZHAO T, LI H J, FENG J, et al. Impact of ABCC2 1249G>A and -24C>T polymorphisms on lacosamide efficacy and plasma concentrations in Uygur pediatric epilepsy patients in China . Ther Drug Monit, 2022. DOI: 10.1097/FTD.0000000000001003.
[46] LAKEHAL F, WURDEN C J, KALHORN T F, et al. Carbamazepine and oxcarbazepine decrease phenytoin metabolism through inhibition of CYP2C19 . Epilepsy Res, 2002, 52(2): 79-83.
[47] CAWELLO W, NICKEL B, EGGERT-FORMELLA A. No pharmacokinetic interaction between lacosamide and carbamazepine in healthy volunteers . J Clin Pharmacol, 2010, 50(4): 459-471.
[48] KADIAN R, KUMAR A. Zonisamide . Treasure Island (FL): StatPearls Publishing, 2023.
[49] MARKOULA S, TEOTONIO R, RATNARAJ N, et al. Lacosamide serum concentrations in adult patients with epilepsy: the influence of gender, age, dose, and concomitant antiepileptic drugs . Ther Drug Monit, 2014, 36(4): 494-498.
[50] VERROTTI A, LATTANZI S, BRIGO F, et al. Pharmacodynamic interactions of antiepileptic drugs: From bench to clinical practice . Epilepsy Behav, 2020, 104(Pt A): 106939. DOI: 10.1016/j.yebeh.2020.106939.
[51] CAWELLO W, MUELLER-VOESSING C, FICHTNER A. Pharmacokinetics of lacosamide and omeprazole coadministration in healthy volunteers: results from a phase I, randomized, crossover trial . Clin Drug Investig, 2014, 34(5): 317-325.
[52] STOCKIS A, VAN LIER J J, CAWELLO W, et al. Lack of effect of lacosamide on the pharmacokinetic and pharmacodynamic profiles of warfarin . Epilepsia, 2013, 54(7): 1161-1166.

基金

2023年江苏省卫生健康委员会特聘医学专家项目资助;江苏省研究型医院学会精益化用药科研基金项目资助(JY202108);CAAE癫痫科研基金—UCB基金项目资助(CU-2022-024)
PDF(942 KB)

Accesses

Citation

Detail
段落导航
相关文章

/

〈 〉